BiotechTube
Home/Pipeline/Tolerizing Therapies

Tolerizing Therapies

Autoimmune Diseases

ClinicalActive (in collaboration with Lilly)

Key Facts

Indication
Autoimmune Diseases
Phase
Clinical
Status
Active (in collaboration with Lilly)
Company
Repertoire Immune Medicines

About Repertoire Immune Medicines

Repertoire Immune Medicines is a Flagship Pioneering-founded biotech leveraging its proprietary DECODE platform to map the immune synapse and discover the specific codes governing T cell-antigen interactions. This platform underpins a pipeline of programmable immune medicines aimed at treating cancer by eliminating tumors and autoimmune diseases by restoring immune tolerance. The company is clinical-stage, has established a significant collaboration with Eli Lilly, and is led by a seasoned team with deep expertise in immunology and drug development.

View full company profile

Therapeutic Areas

OncologyAutoimmune Diseases

Other Autoimmune Diseases Drugs

DrugCompanyPhase
Humira (Adalimumab) BiosimilarNeuCloneEarly Preclinical
HBM7020Harbour BioMedDiscovery
R2006Harbour BioMedDiscovery
R7027Harbour BioMedDiscovery
ImmCelz™ PlatformCreative Medical Technology HoldingsPreclinical
Not specified in provided content3SbioVarious
Gavocabtagene autoleucelastellasPhase 1/2
TYK-101TYK MedicinesPhase 1
HCB206HanchorBioPreclinical
miR-124 ActivatorFormation BioPhase 2
Autologous Cell Therapy CollaborationLupagenPreclinical
Autoimmune Diagnostics Leadership InitiativeVibrant America Clinical LaboratoryCommercial